XNASVOR
Market cap111mUSD
Jan 08, Last price
1.63USD
1D
-1.81%
1Q
148.97%
IPO
-96.19%
Name
Vor Biopharma Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
64.02%
Rev. gr., 5y
%
Revenues
0k
Net income
-118m
L+29.85%
CFO
-100m
L+17.79%
Earnings
Mar 18, 2025
Profile
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 129,528 | 102,378 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (129,528) | (102,378) | ||||
NOPBT Margin | ||||||
Operating Taxes | (1,324) | |||||
Tax Rate | ||||||
NOPAT | (129,528) | (101,054) | ||||
Net income | (117,863) 29.85% | (90,770) 31.97% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 3,391 | 115,975 | ||||
BB yield | -2.24% | -44.09% | ||||
| Debt | ||||||
Debt current | 7,660 | 3,272 | ||||
Long-term debt | 67,490 | 74,552 | ||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (62,025) | (154,834) | ||||
| Cash flow | ||||||
Cash from operating activities | (100,292) | (85,144) | ||||
CAPEX | (1,069) | (8,462) | ||||
Cash from investing activities | 71,008 | (94,091) | ||||
Cash from financing activities | 2,938 | 117,140 | ||||
FCF | (122,548) | (135,609) | ||||
| Balance | ||||||
Cash | 137,175 | 230,245 | ||||
Long term investments | 2,413 | |||||
Excess cash | 137,175 | 232,658 | ||||
Stockholders' equity | (340,150) | (222,980) | ||||
Invested Capital | 530,364 | 512,499 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 67,192 | 39,551 | ||||
Price | 2.25 -66.17% | 6.65 -42.77% | ||||
Market cap | 151,182 -42.52% | 263,017 -39.11% | ||||
EV | 89,157 | 108,183 | ||||
EBITDA | (126,036) | (99,853) | ||||
EV/EBITDA | ||||||
Interest | 1,324 | |||||
Interest/NOPBT | ||||||